Table 2 BNP and NT-proBNP levels, expressed as median (IQR) during treatment with placebo or linagliptin
| Â | Placebo | Linagliptin | Placebo-subtracted change | ||||
|---|---|---|---|---|---|---|---|
Pre | Post | Change | Pre | Post | Change | ||
BNP | |||||||
 All | 22.9 (10.0–42.8) | 21.3 (10.0–52.6) | 0.0 (−0.9 to 15.2) | 19.6 (10.0–44.3) | 22.6 (10.0–39.3) | 0.0 (−2.7 to 7.8) | 0.0 (−19.0 to 1.7) |
 No CKD | 11.4 (10.0–23.3) | 11.9 (10.0–29.5) | 0.0 (−0.9 to 0.3) | 10.6 (10.0–21.8) | 12.5 (10.0–27.4) | 0.0 (0.0–4.6) | 0.0 (−1.0 to 1.2) |
 CKD | 38.5 (26.8–80.3) | 56.3 (24.6–107.1) | 7.3 (−0.7 to 26.0) | 44.2 (20.3–129.0) | 37.4 (25.0–78.9) | 0.0 (−9.5 to 12.1) | −17.6 (−46.8 to 0.8) |
NT-proBNPÂ | |||||||
 All | 101.0 (36.5–314.5) | 122.0 (38.0–267.0) | 2.0 (−32.0 to 30.5) | 101.0 (44.0–299.0) | 78.0 (36.0–272.0) | −3.5 (−27.5 to 19.3) | −19.5 (−62.3 to 19.3) |
 No CKD | 46.0 (26.0–101.0) | 57.0 (20.0–167.0) | 0.0 (−12.0 to 20.0) | 51.0 (28.5–121.5) | 41.0 (26.5–99.0) | 3.0 (−17.5 to 17.3) | −2.5 (−35.0 to 15.8) |
 CKD | 218.5 (108.8–554.8) | 261.0 (130.0–696.5) | 4.5 (−57.8 to 109.3) | 238.5 (107.5–611.5) | 184.0 (109.0–483.0) | −17.0* (−59.3 to 23.0) | −50.0# (−101.5 to 18.0) |